Accelerating Medicines Partnership: Type 2 Diabetes Project

AMP T2D is issuing new Request for Proposals (RFPs).

AMP T2D RFP 8b - Responses due by April 25, 2019.

AMP T2D RFP 10 - Responses due by April 25, 2019.

AMP T2D RFP 16 - Responses due by April 25, 2019.

AMP T2D RFP 13 - Responses due by April 25, 2019

The Accelerating Medicines Partnership Type 2 Diabetes Project (AMP T2D), is a multi-sector, pre-competitive partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases, such as diabetes and diabetic complications. This program has created a T2D Knowledge Portal, which is a database of  sophisticated genotypic and phenotypic, and epigenomic information linked to clinical data from large cohorts of diabetes patients. As of 2018, genotypic data from over a million individuals, from 47 individual datasets and covering 73 traits are available for querying at this point. The AMP T2D program is committed to the continued development of state of the art analytical tools and the inclusion of additional datasets of value for researchers to mine and analyze.

Since its launch in 2014, the AMP T2D Knowledge Portal is fast becoming the go to source for deposition of large amounts of diabetes and complications data for published studies. The data are curated and harmonized for querying alongside existing data. The end goal of the project is to have a powerful, publicly available T2D Knowledge Portal with a progressively growing database and analytical tools for identification and validation of effective T2D drug candidates. The 5-year, $58M project has been extended until 2020.

To read the full project plan click here.

Current Funding Opportunities:

New opportunities to be listed soon.

Results & Accomplishments:

Media:

Nature Reviews Drug Discovery (February 27, 2019): Massive NIH-industry project opens portals to target validation

Related Resources:

NIH News Release (June 2016): Diabetes portal adds data, more powerful search tools

Accelerating Medicines Partnership expands reach, potential of type 2 diabetes engine

Press release: Accelerating Medicines Partnership Announces Awards to Advance Research in Type 2 Diabetes

AMP T2D Knowledge Portal

NIH Overview of Accelerating Medicines Partnership Type 2 Diabetes

Accelerating Medicines Partnership

Accelerating Medicines Partnership - Alzheimer's Disease

Accelerating Medicines Partnership: Rheumatoid Arthritis, Systematic Lupus Erythematosus & Related Autoimmune Disorders

Partners:

Private-Sector Partners:
American Diabetes Association*
Amylin*
Eli Lilly and Company*
Janssen Research and Development LLC*
Juvenile Diabetes Research Foundation*
Merck Sharp & Dohme Corp.*
Novartis*
Novo Nordisk*
Pfizer Inc.*
Sanofi US Services*
Takeda*

*Provided financial or in-kind support for this program.

FNIH Contact:

For additional information please contact Tania Kamphaus, Scientific Program Manager, at Tkamphaus@fnih.org or (301) 435-6247.